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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The purpose of this review is to assess the effectiveness of interventions to systematically improve identification of FH in non-specialist
settings compared to usual care (incidental approaches to identify FH in non-specialist settings).
B A C K G R O U N D
Description of the condition
Familial hypercholesterolaemia (FH) is an autosomal-dominant
disease and has long been recognized as a cause of premature coro-
nary heart disease (CHD) (Nordestgaard 2013). In the majority
of people with FH, the disorder is caused by a mutation of the
low-density lipoprotein (LDL) receptor gene which impairs the
proper function of the receptor, thus resulting in very high levels of
plasma cholesterol. This leads to early onset atherosclerosis, caus-
ing excess morbidity and mortality from CHD (Goldstein 1995).
Themajority of people have the heterozygous formof FH(Baumer
2009) with an estimated one in 500 people affected (Foody 2014).
However, more contemporary data suggest that prevalence may
be as high as one in 200, with over 30 million individuals affected
worldwide (Benn 2012; Nordestgaard 2013; Weigman 2015).
Based on predicted prevalence and the number of people cur-
rently diagnosed, it is reported that the majority of affected indi-
viduals remain undiagnosed (Demott 2008). The importance of
early identification is to allow treatment prior to the appearance of
CHD symptoms, since affected individuals have an estimated 100
fold-increase in CHD mortality compared to unaffected adults
(Demott 2008; Nordestgaard 2013). It is estimated that half of
the men with heterozygote FH will have developed CHD by 55
years of age and one third of women by 60 years of age (Marks
2003).
Several national guidelines on identifying and managing FH have
been published (Goldberg 2011;Haralambos 2016;Harada-Shiba
2012; Hata 2002; Knowles 2015; NICE 2008; Nordestgaard
2013; Simon Broome Register Group 1991; Sullivan 2013;
Williams 1993). In these guidelines confirmation of FH diagnoses
involves assessment against one or more specified diagnostic cri-
teria. These diagnostic criteria include:
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• Simon Broome criteria (Simon Broome Register Group
1991). The criteria identify individuals with possible or definite
FH as adults with total cholesterol > 7.5 mmol/L (LDL > 4.9
mmol/L) or children (less than 16 years of age) with total
cholesterol over 6.7 mmol/L (LDL > 4.0 mmol/L), combined
with a family history of premature heart disease or raised
cholesterol or presence of tendinous xanthomata (or a
combination of these) (NICE 2008; Qureshi 2009). This has
been adopted in England and Wales following recommendations
by the National Institute for Health and Care Excellence
(NICE), following a review of non-randomised studies (NICE
2017).
• US MedPed criteria (Williams 1993). These use age-specific
total cholesterol thresholds only and do not incorporate family
history or clinical signs during an examination (Watts 2015).
• Dutch Lipid Clinic Network (DLCN) criteria (Defesche
2004; Reiner 2011; Watts 2011). In Europe, the European
Atherosclerosis Society and the European Society of Cardiology
recommend using the DLCN criteria (Reiner 2015;
Nordestgaard 2013). The DLCN criteria combine five domains:
family history, clinical history, physical examination (presence of
tendinous xanthomata or arcus cornealis (or both)) and LDL-
cholesterol levels. A scoring system then identifies individuals
with a diagnosis of possible, probable or definite FH based on a
scoring criteria (Austin 2004; Haase 2012; Nordestgaard 2013;
Watts 2011).
• Wales has adopted a modified version of the DLCN criteria
that includes triglyceride concentrations (Haralambos 2016).
• Japanese criteria (Harada-Shiba 2012). These criteria
combine LDL levels (180 mg/dL or more), physical examination
(presence of tendinous xanthoma or nodule xanthoma and
family history (relatives in the 2nd degree) of FH or premature
CAD (males younger than 55 years and females younger than 65
years). Individuals meeting two criteria are regarded as having
FH, with the recommendation for further genetic testing. These
supersede previous guidelines developed by the Japanese
Atherosclerosis Society (Hata 2002).
Furthermore, most guidelines recommend that once individu-
als with FH have been diagnosed, they commence high-inten-
sity statin therapy and identify other relatives with the condition
(Goldberg 2011; Gidding 2015; NICE 2017;Nordestgaard 2013;
Sullivan 2013).
Considering the possible assessment and referral pathway, individ-
uals are initially assessed in primary care or another non-specialist
setting. Primary care and non-specialist centres could be a gen-
eral or family practice, an ambulatory or outpatient care centre,
or a community health centre. Subsequent referral may occur to
a specialist, such as lipidologists, endocrinologists, cardiologists,
clinical nurse specialists or geneticists, depending on the organi-
sational infrastructure. The specialist would then confirm the di-
agnosis (including, in many cases, genetic testing), initiate man-
agement and offer cascade screening to other relatives (Bell 2012;
Bell 2013; Troeung 2016).
Description of the intervention
In non-specialised settings, the incidental identification of those
who may be at risk of FH (usual care) may include the following
strategies:
• assessment of FH opportunistically during an unrelated
clinical consultation;
• assessment of FH as part of a routine health check or health
screen;·
• assessment of FH when an individual raises concerns about
their cholesterol or family history of heart disease.
However, FH remains under diagnosed and under treated, with up
to 80% of individuals affected and resulting in major lost oppor-
tunities to prevent premature heart disease (Nordestgaard 2013;
Qureshi 2009).
It has been suggested that a more systematic approach may help
to identify more individuals in the non-specialist setting (Gidding
2015; Reiner 2015; Vallejo-Vaz 2015). These interventions could
include: prospective population screening (Wald 2016); retrospec-
tive searches of health records (Gray 2008); proactive computer-
generated reminders (Qureshi 2016); case-finding by health care
practitioners and review of patient records (Green 2015); and
pathology laboratories reporting back clinicians about patients
who might have FH (Troeung 2016).
How the intervention might work
Prospective population screening programmes have been a suc-
cessful strategy to target specific demographics of the population
more likely to have a condition. For example, the UK National
Health Service faecal occult blood test screening program for early
detection of colorectal cancer targets the population by age (those
aged 60 to 74 years) and has led to a 16% reduction in colorectal
cancer mortality (Hewitson 2007).
Systematic searching of medical records (either manually or elec-
tronically) or pathology laboratory databases (Bell 2012; Gray
2008; Green 2015; Kirke 2015; Weng 2015) could identify indi-
viduals with relevant risk factors for FH, such as a history of raised
cholesterol, premature heart disease, significant family history of
CHD, and clinical signs.
An alert could be added to the medical records of individuals at
risk to remind their doctor to check their cholesterol level. These
reminders are an example of changing clinician behaviour using
antecedent cues (Michie 2004). Agreement could be reached with
local pathology laboratories contacting the primary care physician
by telephone when a very high cholesterol result is processed (Bell
2014).
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Why it is important to do this review
The WHO recognises the need to prevent and control cardio-
vascular disease (CVD), and that managing raised lipids is a key
modifiable risk factor (WHO 2011). Internationally, it is recog-
nised that a universal targeted approach to identify and manage
heterozygote FH is a key priority to prevent CVD (Benn 2012;
Nordestgaard 2013; Reiner 2015; Robinson 2013; Watts 2015).
For successful identification of FH, case finding needs to extend
beyond the specialist lipid clinic to non-specialists in primary care
(NICE 2008) and other community non-health settings, such as
occupational health services (Kirke 2015).
For people who are affected by FH, there is strong evidence for
the benefits of early identification and treatment (Demott 2008;
Marks 2003; NICE 2017). High-intensity lipid-lowering treat-
ment is very effective with a 44% reduction in CHD mortality
(Besseling 2016). However, evidence-based approaches to support
guideline implementation are under developed (Grimshaw 1993;
Michie 2004). Improving the current low detection rate of FH is
urgently needed.
Moreover, identification of index cases will lead to the detection of
affected but asymptomatic relatives, especially those at a younger
age, resulting in early initiation of statin treatment to lower choles-
terol with the recognised reduction in premature mortality, and
long-term morbidity. As 50% of first degree relatives of people
with confirmed FH will also have the condition, cascade screen-
ing by specialists has been shown to be a cost-effective approach
(Marks 2003; Nherera 2011). This has also improved quality of
life in those family members identified (van Maarle 2003).
Toovercome existing gaps in care and reduce the preventable global
burden of disease arising from FH, dissemination of current evi-
dence to healthcare providers and policy makers is needed. This
can inform the development of the most effective evidence-based
guidelines to deliver optimal care for people with FH, thus en-
abling clinicians to expedite diagnosis and initiate effective treat-
ment. Evidence on which strategies are effective for improving
identification of FH is needed in order to prioritise primary health-
care resources and target those individuals at greater risk of devel-
oping premature CHD.
The review may also provide an exemplar for improving identifi-
cation of other common monogenic disorders in the non-special-
ist primary care setting. Furthermore, the evidence may provide
generic findings relevant to developing other pertinent interven-
tions in this context.
O B J E C T I V E S
The purpose of this review is to assess the effectiveness of inter-
ventions to systematically improve identification of FH in non-
specialist settings compared to usual care (incidental approaches
to identify FH in non-specialist settings).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs), cluster-RCTs and non-
randomised study interventions (NRSI). Eligible NRSI are non-
randomised controlled trials, prospective cohort studies, before-
and-after studies, and interrupted-time-series (ITS) studies.
Due to the complex nature of the intervention and setting, we
have included NRSI as we anticipate potential limitations in the
availability of RCTs. NRSI evidence may highlight the need for
research for high-quality RCTs. In addition, NRSI may yield evi-
dence on outcomes for important study processes such as referrals
or longer-term coronary outcomes which are unlikely to be avail-
able from RCTs.
Types of participants
Eligible participants of any age from the general population who
access non-specialist clinical settings and other non-clinical com-
munity settings. Participants who are selected from specialist set-
tings with expertise in lipid disorders will be excluded from the
review. Participants who have a previous diagnosis of FH or other
inherited lipid disorders will also be excluded. If the study contains
both eligible and ineligible participants, the study will be included
if the data on eligible participants can be extracted where at least
70% of the study contains eligible participants.
Definition of term ’non-specialist’ can be found in an appendix
(Appendix 1)
Types of interventions
Interventions that aim to systematically identify people with pos-
sible or definite FH, in non-specialist clinical settings in primary
care and other community settings. Interventions which involve
specialists delivering the interventions in a non-specialist setting
(e.g. FH nurse specialists performing case findings) are also appro-
priate for inclusion.
A systematic intervention for identifying FH is defined as:
• prospective general population screening for FH using
diagnostic criteria;
• retrospective electronic and manual health records search
for participants who might have FH (i.e. based on elevated
cholesterol levels, relevant family history, clinical characteristics,
or combination of these factors);
• proactive computer-generated reminders for participants
who might have FH (i.e. based on elevated cholesterol levels,
past medical history, relevant family history, clinical
characteristics, or combination of these factors);
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• population based case-finding activities (i.e. healthcare
practitioner reviewing patient records and contacting individuals;
pathology laboratories reporting back high cholesterol levels).
These systematic strategies to identify individuals with possible
or definite FH, will be compared with usual care, where partic-
ipants will continue to receive their standard or current medical
care (Reeves 2016). In this situation, usual care for FH identifica-
tion in non-specialist primary care practice will be incidental and
non-systematic during routine consultation with patients. This
includes noting a raised cholesterol during consultation with in-
dividuals presenting with concerns about their personal or family
history. Should usual care vary between geographical settings, a
description of such will be provided.
Where possible, we will compare interventions to each other if the
usual care strategies are similar between or within the studies.
Types of outcome measures
Primary outcomes
1. Diagnosis of definite FH at the end of study follow-up,
defined by a positive genetic mutation test or clinical phenotype
typical of FH (as defined by diagnostic criteria)
2. Diagnosis of possible and probable FH (as defined by
diagnostic criteria) at the end of study follow-up
3. Adverse events at the end of study follow-up (e.g. drug
adverse events, hospitalisations, all-cause mortality)
Definition of the terms definite FH and possible FH can be found
in an appendix (Appendix 1).
Secondary outcomes
1. Cholesterol levels in participants diagnosed with FH (total
cholesterol, LDL cholesterol) at the end of study follow-up, and
from the date of FH diagnosis
2. Cardiovascular mortality and morbidity of FH participants
at end of study follow-up (minimum of one year follow-up)
3. Lipid-lowering treatment prescribed to people with FH
(including stratification of statin prescribing by high, medium,
low potency at end of study)
4. Referral of FH participants at end of study follow-up to a
specialist service
5. Adverse self-reported psychological effects at end of study
follow-up (e.g. worry, anxiety, depression with a validated
instrument)
6. Management errors (e.g. misdiagnosis, inappropriate statin
prescribing, inappropriate referrals to specialists)
Where multiple measurements of the same outcome are reported
at different follow-up times, we plan to report all measurements
as per the categories below:
1. short-term (outcome reported closest to three months of
end of study follow-up (range can include one to four months));
2. medium-term (outcome reported closest to six months of
end of study follow-up (range can include five to nine months));
3. long-term (outcome reported closest to 12 months of end
of study follow-up (range can include over 10 months)).
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
We will identify relevant studies from the Cystic Fibrosis and Ge-
netic Disorders Group’s Inborn Errors of Metabolism Trials Reg-
ister using the term: hyperlipoproteinaemia.
The Inborn Errors of Metabolism Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of the Cochrane
Library), and weekly searches of MEDLINE. Unpublished work
is identified by searching the abstract books of the Society for
the Study of Inborn Errors of Metabolism conference and the
SHS Inborn Error Review Series. For full details of all searching
activities for the register, please see the relevant section of the
Cochrane Cystic Fibrosis and Genetic Disorders Group’s website.
In addition to the above, we will conduct a search of the following
databases combining free text terms and controlled vocabulary
where applicable (Appendix 2):
• Cochrane Central Register of Controlled Trials (CENTRAL
in the Cochrane Library (www.cochranelibrary.com) (all years);
• PubMed (Epub Ahead of print, In process & Other non-
Indexed Citations only) (www.ncbi.nlm.nih.gov/pubmed) (1946
to present);
• MEDLINE (OvidSP, EpubAhead of Print, In-process &
Other Non-Indexed Citations, Ovid MEDLINE Daily and
Ovid MEDLINE) (1946 to present);
• Embase (OvidSP) (1974 to present);
• CINAHL (EBSCOHost) (1937 to present);
• ProQuest Dissertations & Theses Global ProQuest (
www.proquest.com/) (1861 to present);
• Web of Science (CPCI-S) (1898 to present);
• SCOPUS (Elsevier) (1823 to present).
We will search the following trial databases and resources:
• ISRCTN registry (www.isrctn.com/) (all years);
• ClinicalTrials.gov (www.clinicaltrials.gov) (all years);
• WHO International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp.en) (all years)
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Searching other resources
Reference lists
We will check the bibliographies of included studies and any rele-
vant systematic reviews identified for further references to relevant
studies. We will contact the lead authors of the included studies
to identify unpublished material and missing data or information
regarding ongoing studies.
Handsearching
Search strategies for handsearching the following journals can be
found in the appendices (Appendix 3).
• Heart (heart.bmj.com/) (all years)
• Atherosclerosis (www.atherosclerosis-journal.com/) (all years)
• Journal of Clinical Lipidology (www.lipidjournal.com/) (all
years)
• Current Opinion in Lipidology (www.ovid.com/site/catalog/
journals/439.jsp) (all years)
• Journal of Inherited Metabolic Disease (link.springer.com/
journal/10545) (all years)
In addition, we will search the following prospective publication
databases.
• HEART UK (heartuk.org.uk) (All years)
• the FH Foundation (thefhfoundation.org/) (all years)
We will also search the following relevant guideline developers.
• National Institute for Health and Care Excellence (
www.nice.org.uk/ (all years)
• Scottish Intercollegiate Guidelines Network (
www.sign.ac.uk/) (all years)
• National Institute for Health and Care Excellence Clinical
Knowledge Summaries (cks.nice.org.uk/) (all years)
We will also aim to identify any unpublished work by searching
the abstract books of the following major cholesterol conferences.
• the Heart UK Annual Scientific Conference (
heartuk.org.uk) (all years)
• the British Cardiovascular Society Conference (
www.bcs.com) (all years)
• the European Atherosclerosis Society Conference (eas-
society.org) (all years)
We will complement the searches by making contact with experts
and researchers known to be active in the field in order to identify
additional trials, including unpublished and ongoing studies.
Data collection and analysis
Selection of studies
Wewill select studies according to chapter 7 of theCochraneHand-
book for Systematic Reviews of Interventions (Higgins 2011b). We
will save the results from the searches in Endnote reference man-
aging software (Endnote X5). Two authors (JT, MD) will inde-
pendently screen the titles and abstracts of the identified studies to
check for eligibility. We will then retrieve the full texts (were avail-
able) of the potentially eligible studies and two authors (JT, MD)
will independently screen these.We will resolve any disagreements
through discussion, or where necessary, with the assistance of a
third author (JLB).
To guard against potential duplicate publication, we will link mul-
tiple reports using the same study participants. If any uncertainties
arise concerning study eligibility for the review, we will correspond
with the investigators of the study in question. If it is not possible
to resolve any disagreements on whether to include a study with-
out obtaining further information, we will categorize the study in
the review as ’awaiting assessment’ until the additional informa-
tion is obtained from the study authors.
We will record details of studies excluded at the full text stage
together with reasons for exclusion based on the inclusion criteria
for the review.
Data extraction and management
Two authors will independently extract and record data from in-
cluded studies following guidance in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a). We will use
standard data extraction forms, based on the checklist from the
Cystic Fibrosis andGeneticsDisordersGroup, whichwewill mod-
ify to allow relevant data to be captured from all the study designs
which are eligible for inclusion in this review. Where possible we
will pre-pilot themodified version of the data extraction formwith
a minimum of three studies with different study designs.
The data extraction form will include study characteristics such
as study methodology, participant characteristics (including eth-
nic or cultural characteristics, geographical location), sample size,
strategies and characteristics (including process and duration of
intervention), primary and secondary outcome measures, FH di-
agnostic criteria and definitions of other outcomes, and analysis
performed in the original trials.
For NRSI, we will extract additional data on confounding factors,
the comparability of groups on confounding factors, methods used
to control for confounding and on multiple effect estimates (both
unadjusted and adjusted estimates) (Reeves 2011). Confounding
factors need to be associated with both the intervention and the
outcomes, thus are unlikely to be participant-level factors but pop-
ulation- or service-level factors. These may include, but are not
limited to:
• type of health professional(s) delivering the intervention;
• size of the population being assessed;
• workload of the health professional(s)
We plan to resolve any discrepancies in data extraction through
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discussion, or where necessary, through arbitration with a third
author (JLB). One author (JT) will enter data into the Review
Manager Software and a second author (SW) will verify the data
(RevMan 2014).
Assessment of risk of bias in included studies
For all studies, two review authors (NQ and SW) will indepen-
dently assess the risk of bias for each study; and if there is a dis-
agreement, a third author (JLB) will check each assessment and
discuss the outcome until consensus is achieved.
For RCTs, we will assess the risk of bias using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
according to the following domains: random sequence generation;
allocation concealment; blinding of participants and personnel;
blinding of outcome assessment; incomplete outcome data; selec-
tive outcome reporting; and other sources of bias (Higgins 2011c).
For NRSI, we will assess risk of bias for each outcome of interest
in the study using the ROBINS-I tool developed by the Cochrane
Non-Randomised Studies Methods Group (Sterne 2016). The
tool considers seven domains: two domains of bias pre-interven-
tion (bias due to confounding and bias in selection of participants
into the study); one domain of bias at intervention (bias in the
measurement of interventions); and four domains of bias post-
intervention (bias due to departures from intended interventions,
bias due to missing data, bias in measurement of outcomes and
bias in selection of the reported result).
The authors will grade the methods used in each included study
as either a high, low or unclear risk of bias. We will record all
judgements in the ’Risk of bias’ tables, together with the charac-
teristics of each included study and we will prepare a ’Risk of bias’
summary figure. We will contact relevant authors of studies pub-
lished within the past 10 years for missing information or when
further clarification is needed. We will document the outcomes of
the correspondence in the review.
Measures of treatment effect
Where possible, we will report dichotomous outcomes using risk
ratios (RR) together with 95%confidence intervals (95%CIs). For
studies which have used randomisation, we will extract 2x2 data
and estimate crude RRs; however, for studies without randomi-
sation, we will extract RRs which have been adjusted for baseline
differences or the ratio of the RR post-intervention compared to
the RR for pre-intervention. Where studies report other adjusted
measures of effect, e.g. odds ratios, we will extract these and report
them separately.
Where possible, we will report continuous outcomes using mean
differences (MD) together with 95% CIs. For studies which have
used randomisation, we will extract raw data and estimate crude
MDs; however, for studies without randomisation, we will extract
MDs for the absolute change or the relative change, which have
been adjusted for baseline differences.
For studies with a non-randomised study design, we will consider
additional analysis on adjusting for baseline group differences,
with appropriate regression analysis based on the form of the out-
come variables (continuous or binary).
For studies which have used an ITS design, we will extract quan-
titative results from either a regression analysis with time trends
before and after the intervention, adjusted for autocorrelation and
any periodic changes, or from an ARIMA analysis. We will present
the results for the outcomes as the change in level (immediate
effect of the intervention) and the change in slope (longer-term
effect of the intervention). If the results from a study using an ITS
design are only reported as data points in a scanable graph or in a
table, we will attempt to re-analyse the data by contacting study
authors for permission to use their raw study data (Ramsay 2003).
Unit of analysis issues
We will consider whether any unit of analysis errors are made in
the reported analysis for each study. For cluster-randomised stud-
ies, where the analysis may not adjust for the effect of clustering,
if we identify a unit-of-analysis issue, we will attempt to correct
the analysis by re-analysing the presented data. Or if there is in-
sufficient information presented, we will contact the authors to
obtain the necessary information or raw data. If we are not able to
re-analyse the data taking into account clustering, we will report
the uncorrected estimates without a measure of uncertainty (e.g.
95% CI).
For studies that have accounted for repeated measures we will
report their study measures.
Dealing with missing data
Where important data are missing (e.g. standard deviations), we
will contact the authors of studies published less than 10 years
ago to request additional data. Where we are unable to retrieve
missing data, we will conduct a sensitivity analysis to compare
study outcomes grouped by how much data are missing: large
amount (more than 30%); moderate amount (10% to 30%); low
amount (less than 10%). Wewill then discuss the potential impact
of the missing data on the findings of the review.
Assessment of heterogeneity
Clinical heterogeneity
We will consider clinical heterogeneity which can result from dif-
ferences between studies in the characteristics of the populations,
interventions and outcomes. We will fully discuss the influence of
clinical heterogeneity on the observed effects.
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Methodological heterogeneity
It is likely that we will identify heterogeneity as a result of bias
from the different study designs included in the review. We will
fully discuss the influence of methodological heterogeneity on the
observed effects.
Statistical heterogeneity
We will quantify the proportion of variation in the meta-analyses
due to clinical andmethodological heterogeneity using I² (Higgins
2002). We will also visually examine the inconsistency of the 95%
CIs within each meta-analysis. We will describe the proportion
of variability due to heterogeneity using the following values de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011d):
• 0% to 40%: might not be important;
• 30% to 60% may represent substantial heterogeneity;
• 75% to 100% considerable heterogeneity.
Due to the different designs of the included studies, we antici-
pate that we will identify moderate to high levels of heterogeneity
within each meta-analysis; therefore, we will conduct a thorough
examination of the heterogeneity to try to describe reasons for its
presence.
Assessment of reporting biases
Where the meta-analyses contains more than 10 studies, funnel
plots will be used to assess the potential effects of reporting biases.
Where funnel plot asymmetry is apparent, the review authors will
consider possible sources of asymmetry other than publication
bias, for example based on domains of methodological quality, and
conduct appropriate sensitivity analyses.
Data synthesis
We will initially summarise all included studies using narrative
synthesis methods. This will involve the use of narrative text and
tables to summarise data based on the type of intervention and
according to setting, consider outcomes in the light of differences
in study designs and address potential sources of bias, potential
confounding factors and any further methodological limitations
for each of the studies being reviewed, including how these may
have impacted on the study findings. We will then provide a syn-
thesised summary of the studies, including the range and size of
any reported associations and important study characteristics.
Meta-analysis for RCTs and NRSI will be conducted separately.
We will use random-effects models to conduct meta-analyses due
to anticipated differences in the effectiveness of the intervention
by type of intervention, setting, and populations.
We will be perform meta-analysis using the Review Manager
(RevMan) software (RevMan 2014) or Stata version 14 (STATA
2015).
Subgroup analysis and investigation of heterogeneity
In each meta-analysis including at least five studies, the authors
will perform subgroup analyses based on study-level variables, and
will report a P value relating to the statistical test for differences
between subgroups, where appropriate. We will consider the fol-
lowing characteristics:
• mode of diagnosis for FH (genetic or clinical);
• age of participant (under 10 years of age or 10 years of age
and above);
• type of systematic intervention (prospective population
screen, retrospective computer search, proactive computer
reminders, population-based case finding);
• type of setting (primary medical care, employer-based
clinics, community pharmacists).
We will undertake subgroup analyses using RevMan (RevMan
2014) or Stata version 14 (STATA 2015). We anticipate that due
to the complexity of the intervention that most studies will in-
clude complex interventions and therefore we will group studies
primarily based on similarities between outcome measures.
Sensitivity analysis
We will assess the impact of methodological quality on the results
of themeta-analyses by re-analysing only those studies with a over-
all low risk of bias. We will compare the pooled effect size from
this secondary analyses to the pooled effect size from the original
analyses. We will report sensitivity analyses in table format within
this review.
Summary of findings tables
The review authors will create ’summary of findings’ table follow-
ing theGRADE approach suggested in theCochrane Handbook for
Systematic Review of Interventions (Schünemann 2011a). This will
state the participant population setting, intervention, comparison,
and main outcome measures. In addition, the tables will present
the quality rating of the evidence as ’high’, ’moderate’, ’low’, or
’very low’ using the following five GRADE considerations:
• risk of bias (serious or very serious);
• inconsistency (serious or very serious);
• indirectness (serious or very serious);
• imprecision (serious or very serious);
• publication bias (likely or very likely).
For NRSI we will also consider the following factors:
• size of effect (large or very large);
• confounding (either reduces the demonstrated effect or
increases the effect if no effect was observed (yes or no)).
In GRADE, we will rate NRSI initially as low quality and down-
grade or upgrade according to GRADE guidelines, if appropriate.
We will present outcomes for these studies in separate tables from
outcomes for the results of RCTs.
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Appendix 1. Glossary of terms
Term Definition
Definite FH
(Simon Broome
criteria)
Adult = total cholesterol levels > 290 mg/dL (7.5 mmol/L) or LDL-C > 190 mg/dL (4.9
mmol/L)
Child less than 16 years of age = total cholesterol levels > 260 mg/dL (6.7 mmol/L) or LDL-
C > 155 mg/dL (4.0 mmol/L)
Plus at least one of the two:
1. plus physical finding = tendinous xanthomas, or tendinous xanthomas in first or second-
degree relative
OR
2. DNA-based evidence of an LDL-receptor mutation, familial defective apo B-100, or a
PCSK9 mutation
Non-specialist a person who is not an expert or does not have specialist subject knowledge
Possible FH
(Simon Broome
criteria)
Adult = total cholesterol levels > 290 mg/dL (7.5 mmol/L) or LDL-C > 190 mg/dL (4.9
mmol/L)
Child = less than 16 years of age = total cholesterol levels > 260 mg/dL (6.7 mmol/L) or
LDL-C > 155 mg/dL (4.0 mmol/L)
Plus at least one of the two:
1. family history of at least one of the following:
- myocardial infarction at 60 years or younger in first-degree relative OR
- myocardial infarction at 50 years or younger in second-degree relative
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(Continued)
OR
2. family history of elevated total cholesterol:
- > 290 mg/dL (7.5 mmol/L) in adult first- or second-degree relative OR
- > 260 mg/dL (6.7 mmol/L) in child, brother or sister aged younger than 16 years
Appendix 2. Search methods - electronic searching
Database Resource Search dates Strategy
CENTRAL, the Cochrane Li-
brary
via the Cochrane Library: (
www.cochranelibrary.com/)
(All years) #1.Hyperlipoproteinemia Type II [MeSH
descriptor]
#2. familial hypercholesterolaemia:ti,ab
#3. Hyperlipoproteinemias [MeSH descrip-
tor]
#4. ”hyperlipoproteinemia type IIb“
#5. ”hyperlipoproteinemia type 2 ti,ab“
#6. ”hyperlipoproteinemia type 2b ti,ab“
#7. ”hyperlipoproteinemia type 2a“
#8. ”hyperlipoproteinemia type IIa“
#9. ”Hyperlipidemia, Familial Combined“
[MeSH descriptor]
#10. ”Hyperlipoproteinemia Type I“ [MeSH
descriptor]
#11. ” Hyperlipoproteinemia Type IV“
[MeSH descriptor]
#12. ”lipoprotein lipase deficiency“
#13. ”inherited hypercholesterolaemia“
#14. ”inherited hypercholesterolemia“
#15. “familial hyperchylomicron”
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7
or #8 or #9 or #10 or #11 or #12 or #13 or
#14 or #15
PubMed (www.ncbi.nlm.nih.gov/
pubmed)
(1946 to present) #1.hypercholesterol*[Title/Abstract]
#2.hyperlipoprotein* [Title Abstract]
#3.familial hypercholesterolemia [Title Ab-
stract]
#4. familial hypercholesterolaemia [Title Ab-
stract]
#5. familial hyperlipoproteinemia (Title Ab-
stract]
#6. familial hyperlipoproteinaemia (Title Ab-
stract]
#7. familial hypercholesterolemia with hy-
perlipidemias [Title Abstract]
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(Continued)
#8. familial combined hyperlipidemia [Title
Abstract]
#9. hypertriglyceridemia, familial [Title Ab-
stract]
#10. hypertrigly* [Title Abstract]
#11. hyperlipoproteinemia TYPE 2 [Title
Abstract]
#12. hyperlipoproteinemia TYPE 2A [Title
Abstract]
#13. hyperlipoproteinemia TYPE 2B [Title
Abstract]
#14. hyperlipoproteinaemia TYPE 2 [Title
Abstract]
#15. hyperlipoproteinaemia TYPE 2A [Title
Abstract]
#16. hyperlipoproteinaemia TYPE 2B [Title
Abstract]
#17. combined hyperlipidemia, familial [Ti-
tle Abstract]
#18. familial lipoprotein lipase deficiency
[Title Abstract]
#19.autosomal dominant
hypercholesterolemia [Title Abstract]
#20. (#1 or #2 or #3 or #4 or #5 or #6 or #7
or #8 or #9 or #10 or #11 or #12 or #13 or
#14 or #15 or #16 or #17 or #18 or#19)
#21. general practice [Title Abstract]
#22. primary health care [Title Abstract]
#23. general Practitioner [Title Abstract]
#24. GP [Title Abstract]
#25. community [Title Abstract]
#26. (#21 or #22 or #23 or #24 or #25)
#27. detect* [Title Abstract]
#28. diagnosis [Title Abstract]
#29. diagnose* (Title Abstract]
#30. laborator* [Title Abstract]
#31. patholog* [Title Abstract]
#32. database [Title Abstract]
#33. record [Title Abstract]
#34. screen* [Title Abstract]
#35. mass screen [Title Abstract]
#36. family [Title Abstract]
#37. familial [Title Abstract]
#38. audit [Title Abstract]
#39. (#27 or #28 or #29 or #30 or #31 or #
32 or #33 or #34 or#35 or #36 or #37 or #
38)
#40.(#20 and #26 and #39)
13Strategies for identifying familial hypercholesterolaemia in non-specialist clinical settings (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
MEDLINE (OvidSP) (1946 to present) 1.((familial or inherited) adj2 hypercholes-
terol?emia$).tw.
2. Hyperlipoproteinemia Type II/
3. (Hyperlipoprotein?emia$ adj (type II or
type IIa or type IIb or type 2 or type 2a or
type 2b)).tw
4. 1 or 2 or 3
5. general practice$.tw.
6. GP.tw.
7. (primary adj (health or care)).tw.
8. ((family or community) adj (medicine or
practice)).tw.
9. Primary Health Care/
10. exp General Practice/
11. 5 or 6 or 7 or 8 or 9 or 10
12. ((((medical or health or patient$ or elec-
tronic) and record$ or database$ or data or
audit or reminder$ or tool$)) or (diagnos$ or
identif$ or detect$)).tw
13. 11 and 12
14. laborator$.tw.
15. Laboratories/
16. patholog$.tw.
17. Pathology/or Pathology, Clinical/
18. 14 or 15 or 16 or 17
19. (record$ or database$ or data or audit or
tool$ or daignos$ or identif$ or detetct$).tw
20. 18 and 19
21. screen .tw.
22. mass screening/
23. 21 or 22
24. 23 and (11 or 18)
25. ((family or relative$) and test$).tw.
26. 13 or 20 or 24 or 25
27. 4 and 26
Embase (Ovid SP) (1974 to present) 1. HYPERLIPOPROTEINEMIA/
2. Hypercholesterolaemia.mp.
3. Hypercholesterolaemia.tw.
4. Hyperlipoproteinemia.mp
5. hyperlipoproteinemia.tw.
6. familial hypercholesterolaemia/
7. hypertriglycer$.tw.
8. hyperlipid$.tw.
9. lipoprotein lipase deficienc$.tw.
10. hyperlipoproteinemia Type 2.tw.
11. autosomal dominant hypercholesterol$.
tw.
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(Continued)
12. familial hypertriglyceridemia$.tw.
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
or 10 or 11 or 12
14. general practice.tw.
15. GP.tw.
16. primary health care.tw.
17. community.tw.
18. 14 or 15 or 16 or 17
19. laboratory.tw.
20. laboratories.tw.
21. screen.tw.
22. mass screening.tw.
23. detection.tw.
24. audit.tw.
25. record.tw.
26. 19 or 20 or 21 or 22 or 23 or 24 or 25
29 13 and 18 and 26
CINAHL (EBSCOHost) (1937 to present) S1(MH ”familial hypercholesterolemia” OR
MH“hypertriglyceridemia”ORMH“hyper-
lipidemia” ORMH “hyperlipoproteinemia”)
S2 (TI “clinic” OR TI “clinical practice” OR
TI “general practice” OR TI “gp” OR TI
“general practitioner” OR TI “community”
ORTI”primary care”ORTI “primary health
care” OR TI “primary healthcare”)
S3 (TI “detection” OR TI “database” OR
TI “laboratory” OR TI “audit” OR TI
“screening” OR TI “mass screening” OR
TI “records” OR TI “identification” OR TI
“identity”)
S4 S1 AND S2 AND S3
ProQuest Dissertations &
Theses
(www.proquest.com/) (1861 to present) ti(familial hypertriglyceridemia) OR ti(hy-
percholesteremia) OR ti(hyperlipidemia)
OR ti(familial combined hyperlipidemia)
AND ti(mass screening) OR ti(audit) OR ti
(diagnosis) OR ti(identifying) OR ti(identify
risk) OR ti(database) OR ti(detection) AND
ti(general practice) OR ti(general practition-
ers) OR ti(clinical practice) OR ti(primary
care) OR ti(primary health care) OR ti(com-
munity)
WEB OF SCIENCE (CPCI-S) (1898 to present) #1 TS=((familial hypercholesterolaemia)OR
TS=(familial hypercholesterolemia) OR TS=
(hyperlipidaemia) OR TS= (hyperlipidemia)
OR TS= (familial combined hyperlipi-
daemia) OR TS= (familial combined hyper-
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(Continued)
lipidemia) OR TS= (hyperlipoproteinaemia)
OR TS= (hyperlipoproteinemia) Or TS=(fa-
milial hypertriglyceridemia) OR TS=(famil-
ial hypertriglyceridaemia))
#2 TI=((screen) OR TI =(mass screen) OR
TI= (audit) OR TI= (detect*) OR TI=
(identify) OR TI= (identification) OR TI=
(record)ORTI= (diagnose) ORTI=(diagno-
sis))
#3 TI=((GP) OR TI= (general practice) OR
TI = (general practitioner) OR TI=(primary
health) OR TI= (primary health care) OR
TI= (primary healthcare) OR TI = (labora-
tory) OR TI = (community))
#1 AND #2 AND #3
SCOPUS (Elsevier) (1823 to present) familial PRE/1 hyperc-
holesterolaemia OR hyperlipidemia OR hy-
perlipidaemia OR hyperlipoproteinemia OR
hyperlipoproteinaemia OR hypertriglycero-
laemiaORhypercholesterolaemiaORhyper-
cholesterolemia AND mass PRE/1 screen-
ing OR diagnosis OR audit OR detect OR
record OR database OR identify OR iden-
tification AND general practice OR general
practitioner OR gp OR primary health care
OR primary healthcare OR community OR
laboratory OR clinic OR clinical practice
ISRCTN registry (www.isrctn.com/) (All years) ADVANCED SEARCH
Search terms: hypercholesterolaemia OR
hypercholesterolemia OR hyperlipidemia
OR Or hyperlipidaemia OR hyperlipopro-
teinaemia OR hyperlipoproteinemia OR hy-
pertryglycerolaemia
Condition: familial hypercholesterolaemia
OR familial hypercholesterolemia
Clinical Trials.gov (www.clinicaltrials.gov) (All years) ADVANCED SEARCH
Condition: familial hypercholesterolemia
Study type: All studies
WHO International Clinical
Trials Registry Platform (IC-
TRP)
(www.who.int/ictrp.en) (All years) ADVANCED SEARCH
Search 1: Title: hypercholesterolaemia AND
Condition: familial hypercholesterolaemia
Search 2: Title: hypercholesterolemia AND
Condition: familial hypercholesterolemia
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Appendix 3. Handsearching
Grey literature Resource Search dates Strategy
HEART UK
The FH Foundation
(heartuk.org.uk)
(the fhfoundation.org/)
(All years) familial hypercholesterolaemia OR familial hy-
percholesterolemia OR hyperlipidemia OR hy-
perlipidaemia OR inherited hypercholestero-
laemia OR inherited hypercholesterolemia OR
hyperlipoproteinaemia OR hyperlipoproteine-
mia
National Institute for Health
and Care Excellence
Scottish Intercollegiate Guide-
lines Network
National Institute for Health
and Care Excellence Clinical
Knowledge Summaries
(www.nice.org.uk/)
(www.sign.ac.uk)
(cks.nice.org.uk/)
(All years) familial hypercholesterolaemia OR familial hy-
percholesterolemia OR hyperlipidemia OR hy-
perlipidaemia OR inherited hypercholestero-
laemia OR inherited hypercholesterolemia OR
hyperlipoproteinaemia OR hyperlipoproteine-
mia
HEART UK Annual Scientific
Conference(s)
British Cardiovascular Society
Conference(s)
European Atherosclerosis Soci-
ety Conference(s)
(heartuk.org.uk)
(www.bcs.com)
(www.eas-society.org)
(All years) familial hypercholesterolaemia OR familial hy-
percholesterolemia OR hyperlipidemia OR hy-
perlipidaemia OR inherited hypercholestero-
laemia OR inherited hypercholesterolemia OR
hyperlipoproteinaemia OR hyperlipoproteine-
mia amilial hypercholesterolaemiaOR autosomal
dominant familial hypercholesterolemia
Jounals (reference lists):
Heart
Atherosclerosis
Journal of Clinical Lipidology
Current Opinion in Lipidology
Journal of Inherited Metabolic
Disease
(heart.bmj.com/)
(www.atherosclerosis-
journal.com)
(www.lipidjournal.com/)
(www.ovid.com/site/catlog/
journals/439.jsp)
(link.springer.com/journal/
10545)
(All years) familial hypercholesterolaemia OR familial hy-
percholesterolemia OR hyperlipidemia OR hy-
perlipidaemia OR inherited hypercholestero-
laemia OR inherited hypercholesterolemia OR
hyperlipoproteinaemia OR hyperlipoproteine-
mia
C O N T R I B U T I O N S O F A U T H O R S
Roles and Responsibilities
Protocol stage: (draft the protocol): NQ, JK, SW, J LB, JT, MD
Review stage: (select studies for inclusion): NQ, JT, MD, J LB
Review stage: (data extraction): SW, JT, MD, J LB
Review stage: JT, MD (contact authors for additional information)
Review stage: (enter data into ReVMan) JT, SW
Review stage: (carry out analysis) NQ, SW, J LB
Review stage: (interpretation of data) NQ, SW, JK, J LB
Review stage: (writing the final review) NQ, JK, SW, J LB, JT, MD
Update stage: (update the review) NQ, SW, JT
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